Myaza 100mg - Azacitidine for Injection

---

1. Myelodysplastic Syndromes (MDS) – A group of disorders in which the bone marrow produces abnormal blood cells.
2. Acute Myeloid Leukemia (AML) – A type of cancer affecting white blood cells.
3. Chronic Myelomonocytic Leukemia (CMML) – A rare blood cancer that affects monocytes.
4. Pre-leukemic Conditions – Prevents the progression of MDS into full-blown leukemia.
5. Bone Marrow Disorders – Helps improve the bone marrow’s ability to produce healthy blood cells.

---

1. Azacitidine blocks DNA methylation, a process that cancer cells use to silence tumor-suppressor genes.
2. By inhibiting DNA methyltransferase, it restores the normal function of these genes, slowing down cancer progression.
3. It also incorporates into RNA, interfering with protein synthesis and inducing apoptosis (programmed cell death) in abnormal cells.

---

1. Standard dose: 75 mg/m² (body surface area) per day for 7 consecutive days, repeated every 28 days.
2. The dose may be adjusted depending on patient response and blood test results.

---

1. Given as an injection (subcutaneous or IV infusion).
2. Administered once daily for 7 days in each treatment cycle.
3. Treatment cycles are usually repeated every 4 weeks.
4. Must be administered by a healthcare professional—do not self-administer.

---

1. Nausea and vomiting
2. Fatigue and weakness
3. Fever and chills
4. Injection site reactions (pain, redness, swelling)
5. Low blood cell counts (anemia, neutropenia, thrombocytopenia)

1. Severe bone marrow suppression – Increased risk of infections and bleeding.
2. Liver toxicity – Symptoms include yellowing of the skin/eyes, dark urine.
3. Kidney problems – Reduced urine output, swelling in legs.
4. Severe allergic reactions – Rash, difficulty breathing, swelling of the face.
5. Heart issues – Chest pain, irregular heartbeat.

---

1. Bone Marrow Suppression: May cause dangerously low blood cell counts.
2. Infections: Patients must be monitored for fever and signs of infection.
3. Liver & Kidney Function: Regular monitoring is required.
4. Pregnancy & Breastfeeding: Not recommended—can harm the fetus.
5. Bleeding Disorders: Avoid if you have active bleeding issues.

---

Drug Interactions (Medications That May Interact)

1. Live vaccines – Avoid receiving live vaccines while on treatment.
2. Immunosuppressants (e.g., Cyclosporine, Tacrolimus) – May increase the risk of infections.
3. Blood thinners (Warfarin, Aspirin) – May increase the risk of bleeding.
4. Nephrotoxic drugs (Cisplatin, Amphotericin B) – May worsen kidney function.

---

1. Do not take Myaza if allergic to Azacitidine or its ingredients.
2. Signs of an allergic reaction:
   1. Swelling of face, lips, or throat
   2. Difficulty breathing
   3. Severe rash or itching
   4. Dizziness or fainting

---

1. Store at 2°C - 8°C (Refrigerated).
2. Do not freeze.
3. Keep away from light and moisture.
4. Use the reconstituted solution within the recommended time.

---

1. Severe nausea and vomiting
2. Profound bone marrow suppression (high risk of infections and bleeding)
3. Kidney and liver failure

1. Seek immediate medical attention.
2. Hospitalization and supportive care may be required.

---

1. If a dose is missed, consult your doctor immediately.
2. Do not double the dose to make up for a missed injection.
3. Follow the prescribed treatment schedule strictly.